Clinical and economic impact of oral ondansetron for vomiting in a pediatric emergency department.

In this study, we determine the clinical impact of 1 dose of oral ondansetron for children with vomiting and evaluate the economic consequences of its use. The strategies compared were administering oral ondansetron in addition to oral rehydration therapy (group A) versus oral rehydration solution alone (group B) in children attended to for vomiting in a pediatric emergency department. The study population was 1871 children between 0 and 14 years of age treated for vomiting during a 2-year period (2009-2010). Outcome measures were need for intravenous rehydration, length of stay in the emergency department, return visits, and hospitalization. Estimates of the costs in the emergency department and hospitalization were derived from administrative databases. During the study period, 580 (31%) of 1871 patients received oral rehydration therapy. Oral ondansetron before oral rehydration solution was used in 109 (18.8%) of 580 patients. An equal number of patients not receiving ondansetron were randomized and analyzed for comparison (group B). Patients of group A had a significantly decreased risk of hospitalization (relative risk, 0.22; 95% confidence interval, 0.08-0.63) and intravenous rehydration (relative risk, 0.31; 95% confidence interval, 0.14-0.63), but there were no differences in the length of stay or return visits to the emergency department. There were no differences in the medical costs between both groups in the emergency department (US $22,078 vs US $21,987, respectively). The hospitalization cost was US $9600 for group A and US $25,079 for group B, providing a 73.7% saving. In conclusion, the administration of oral ondansetron to children with vomiting in the emergency department is clinically effective and results in significant economic savings.

[Neonatal screening of hemoglobinopathies and G6PD deficiency in Catalonia (Spain). Molecular study of sickle cell disease associated with alpha thalassemia and G6PD deficiency]. / Cribado neonatal de hemoglobinopatías y déficit de glucosa-6-fosfato deshidrogenasa (G6PD) en Cataluña. Estudio molecular de la anemia falciforme asociada a alfatalasemia y déficit de G6PD.

BACKGROUND AND OBJECTIVE: The prevalence of hemoglobinopathies and glucose-6-phosphate dehidrogenase (G6PD) deficiency in the Catalan neonatal population is increasing due to immigration. Coinheritance of more than a single RBC genetic defect is becoming more frequent and diagnostic pitfalls are also increasing. We intended to demonstrate the need to perform an early diagnosis of sickle cell disease (SCD) by means of neonatal screening, to establish the prevalence of SCD associated with alpha thalassemia and G6PD deficiency and to identify genotypes associated with sickle cell disease and G6PD deficiency. PATIENTS AND METHOD: 4,020 blood samples from newborns were screened. For the screening of hemoglobinopathies the high performance liquid chromatography method was used and for G6PD deficiency the fluorescent spot test was employed. We studied the association between betaS gene and alpha thalassaemia del-3.7 Kb. SCD and G6PD deficiency genotypes were established. RESULTS: Prevalence of SCD in population at risk was 1/475 newborns. Prevalence of G6PD deficiency in population at risk was 1/43, and in autochthonous population was 1/527 newborns. In all the cases, sickle hemoglobin was confirmed by ARMS (amplification refractory mutation system). Association between betaS gene and alpha thalassaemia del-3.7 Kb was found in 32.2% of the samples, and an association between betaS gene and G6PD deficiency was observed in 7% of the samples. CONCLUSIONS: This study confirms the high prevalence of SCD and G6PD deficiency in population at risk as well as their genetic and clinical heterogeneity. The study of genotype/phenotype relationships allows a better knowledge of molecular mechanism and is useful to establish suitable criteria of diagnosis.

Cribado neonatal de hemoglobinopatías y déficit de glucosa-6-fosfato deshidrogenasa (G6PD) en Cataluña. Estudio molecular de la anemia falciforme asociada a alfatalasemia y déficit de G6PD / Neonatal screening of hemoglobinopathies and G6PD deficiency in Catalonia (Spain). Molecular study of sickle cell disease associated with alpha thalassemia and G6PD deficiency

Fundamento y objetivo: Con los flujos inmigratorios se ha elevado la prevalencia de hemoglobinopatías y déficit de glucosa-6-fosfato deshidrogenasa (G6PD) en nuestra población. La probabilidad de encontrar en un individuo más de un defecto del eritrocito es elevada, lo que comporta una mayor heterogeneidad clínica y dificultades diagnósticas. El objetivo de este trabajo ha sido realizar el diagnóstico precoz de la anemia falciforme mediante cribado neonatal, analizar la prevalencia de herencia conjunta de alfatalasemia, déficit de G6PD y hemoglobina S e identificar los genotipos asociados. Pacientes y método: Se ha estudiado a 4.020 recién nacidos (RN) de población de riesgo y autóctona. El cribado neonatal de hemoglobinopatías se realizó mediante cromatografía líquida de alta resolución y el de déficit de G6PD mediante la técnica de la mancha fluorescente. Se analizó molecularmente la asociación entre el gen ßS y alfatalasemia con deleción ­3.7 Kb. Finalmente se estableció el genotipo de los casos de déficit de G6PD. Resultados: La prevalencia de anemia falciforme en población de riesgo fue de 1/475 RN, y la de déficit de G6PD, de 1/43 RN en población de riesgo y de 1/527 RN en población autóctona. La hemoglobina S se confirmó mediante ARMS (amplification refractory mutation system). La asociación entre el gen ßS y la alfatalasemia con deleción ­3.7 Kb fue de un 32,2%, y entre el gen ßS y el déficit de G6PD, de un 7%. Conclusiones: Se confirma la elevada prevalencia de la anemia falciforme y del déficit de G6PD en población de riesgo, así como la elevada heterogeneidad molecular de ambos defectos. El conocimiento de los genotipos asociados y su relación con la expresión clínica es de gran utilidad para establecer criterios adecuados de diagnóstico y pronóstico

Background and objective: The prevalence of hemoglobinopathies and glucose-6-phosphate dehidrogenase (G6PD) deficiency in the Catalan neonatal population is increasing due to immigration. Coinheritance of more than a single RBC genetic defect is becoming more frequent and diagnostic pitfalls are also increasing. We intended to demonstrate the need to perform an early diagnosis of sickle cell disease (SCD) by means of neonatal screening, to establish the prevalence of SCD associated with alpha thalassemia and G6PD deficiency and to identify genotypes associated with sickle cell disease and G6PD deficiency. Patients and method: 4,020 blood samples from newborns were screened. For the screening of hemoglobinopathies the high performance liquid chromatography method was used and for G6PD deficiency the fluorescent spot test was employed. We studied the association between ßS gene and alpha thalassaemia del-3.7 Kb. SCD and G6PD deficiency genotypes were established. Results: Prevalence of SCD in population at risk was 1/475 newborns. Prevalence of G6PD deficiency in population at risk was 1/43, and in autochthonous population was 1/527 newborns. In all the cases, sickle hemoglobin was confirmed by ARMS (amplification refractory mutation system). Association between ßS gene and alpha thalassaemia del-3.7 Kb was found in 32.2% of the samples, and an association between ßS gene and G6PD deficiency was observed in 7% of the samples. Conclusions: This study confirms the high prevalence of SCD and G6PD deficiency in population at risk as well as their genetic and clinical heterogeneity. The study of genotype/phenotype relationships allows a better knowledge of molecular mechanism and is useful to establish suitable criteria of diagnosis

Reflujo vesico-ureteral en pediatría: ¿ha cambiado el papel de la cistografía? / Vesicoureteral reflux in pediatrics: has the role of voiding cystourethrogram changed?

Fundamento. El diagnóstico precoz del reflujo vesicoureteral(RVU) puede ayudar a evitar el desarrollo deReflux vesicoureteral en pediatria: ha canviat elpaper de la cistografia?Ester Parada, Nabil Abu-Hadwan, Francesc Mir, José Maria Inoriza, Teresa Carrión,Joan Manel Torres, Joan Agulló, Pere Plaja.Hospital de Palamós. Palamós (Girona)nefropatía de reflujo pero a la vez puede condicionar eluso demasiado generalizado de exploraciones complementariasinvasivas. Es necesario valorar periódicamente elrendimiento de las exploraciones complementarias que solicitamosen el marco de la mejora de las técnicas de diagnóstico,tanto prenatal como postnatal.Objetivo. Valorar las indicaciones y el rendimiento dela CUMS en el estudio de alteraciones renales de diagnósticoprenatal y en el seguimiento de las infecciones deltracto urinario (ITU).Método. Revisión retrospectiva de las historias clínicasde pacientes de 0-4 años en los que se ha realizado unaCUMS en nuestro hospital entre enero de 2001 y agosto de2004.Resultados. Se han estudiado 128 pacientes, en el 75%de los cuales se solicitó CUMS a raíz del diagnóstico de ITUy en el resto como seguimiento de alteraciones renales dediagnóstico prenatal. Se detectó RVU en el 17.2% de lospacientes: el 12.9% de los estudiados por diagnóstico prenataly el 18.7% por ITU. Dos de los pacientes presentaronuna infección de orina post-CUMS.Conclusiones. A pesar de los avances en el diagnósticoprenatal, la presencia de RVU en el 18.7% de los pacientescon antecedente de ITU avala el papel de la CUMS en el estudiode estos pacientes

Background. The early diagnosis of vesicoureteral reflux(VUR) is important for the prevention of its progressionto reflux nephropathy; however, invasive and uncomfortabletechniques are required. The use of suchprocedures ought to be assessed periodically in the evolvingscenario of technological advances in prenatal andpostnatal diagnosis.Objective. To assess the yield of voiding cystourethrogram(VCUG) in the evaluation of congenital renal abnormalitiesand urinary tract infections (UTI).Method. We retrospectively reviewed the medicalcharts of patients younger than 4 years of age who underwentVCUG between January 2001 and August 2004 at ourhospital.Results. One-hundred and twenty-eight patients underwentVCUG during the study period, 75% of them aftera UTI and the rest because of prenatal diagnosis of renalmalformations. RVU was diagnosed in 17.2% of thepatients: 12.9% of patients with renal malformations and18.7% of patients with history of UTI. Two patients developeda UTI after the VCUG was performed. DMSA scanwas performed in 18 of the 22 patients with VUR, and 12of them were found to have renal scarring. Conclusions. Despite the improvements in prenataldiagnosis of renal malformations, the detection of VUR ina significant proportion of patients as a result of a UTIconfirms the importance of VCUG in the evaluation ofpatients with UTI